AMGN250103C370000
- 0.00
- 0.000.00%
Amgen Newsroom
FDA Issues First Draft Guidance on Use of AI in Drug, Medical Device Development
Amgen (NASDAQ:AMGN) Is Paying Out A Larger Dividend Than Last Year
Express News | Amgen UK: Imdylltra Granted Conditional Marketing Authorisation for Third-Line Treatment of Extensive-Stage Small Cell Lung Cancer in UK
Amgen's IMDYLLTRA▼ (Tarlatamab) Granted a Conditional Marketing Authorisation for Third-Line Treatment of Extensive-Stage Small Cell Lung Cancer in the United Kingdom
These 4 Measures Indicate That Amgen (NASDAQ:AMGN) Is Using Debt Extensively
Viking Therapeutics Among Potential Buyout Candidates: Oppenheimer
Amgen Inc. (AMGN) Is a Trending Stock: Facts to Know Before Betting on It
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields
CMB International: Maintains INNOVENT BIO's "Buy" rating, with the Target Price raised to 57.67 HKD.
CMB International has released a research report stating that it maintains a "Buy" rating for INNOVENT BIO (01801), being bullish on the global potential of INNOVENT's Innovative Drugs pipeline, and has raised the target price to HKD 57.67 (previous value: HKD 55.21; WACC: 9.5%, perpetual growth rate: 3.5%). The company has licensed the global rights of the new DLL3ADC (IBI3009) to Roche, receiving an upfront payment of USD 80 million and up to USD 1 billion in milestone payments and sales sharing. The drug is expected to receive IND approval for global Phase 1 research in December 2024. Regarding the DLL3 target, besides
Piper Sandler has lowered Amgen's Target Price to $310.
Gelonghui, January 2 | Piper Sandler: Downgraded Amgen's Target Price from $344 to $310, maintaining a "Shareholding" rating. (Gelonghui)
After experiencing a bumper harvest in 2024, the USA ETF may encounter setbacks this year.
The USA Exchange Traded Fund (ETF) received a record inflow of $1.1 trillion in 2024, but entering 2025, rapid growth may face more obstacles.
Piper Sandler Initiates Amgen(AMGN.US) With Buy Rating, Announces Target Price $310
Amgen Is Maintained at Overweight by Piper Sandler
Analyst Expectations For Amgen's Future
Amgen Analyst Ratings
The competition is fierce! Musk once said that "Tirzepatide", which is more effective than semaglutide, will be launched in China. Who will dominate the weight loss drug market in 2025?
① Today, Eli Lilly and Co announced the official launch of tirzepatide in China, covering both type 2 diabetes and weight loss, and it is already available on some online platforms; ② Musk has claimed that tirzepatide is better than semaglutide, while the market is more focused on the pricing of tirzepatide and whether it will be included in medical insurance; ③ The competition in the GLP-1 sector will become even more intense in 2025, with Jiangsu Hengrui Pharmaceuticals, INNOVENT BIO, and Gan & Lee Pharmaceuticals receiving widespread attention.
Express News | Amgen Inc : Piper Sandler Cuts Target Price to $310 From $344
Dogs Of The Dow: Top 10 High-Yield Stocks Offering Dividends Up To 6.8% In 2025
Express News | UK's Mhra: Tarlatamab Approved to Treat Adult Patients With Small Cell Lung Cancer
These Are the Best and Worst Stocks This Year -- Barrons.com